H.C. Wainwright analyst Boobalan Pachaiyappan initiated coverage of Entrada Therapeutics with a Buy rating and $25 price target. The company’s technology platform provides "unprecedented flexibility and capability" with respect to drug delivery, the analyst tells investors in a research note. The firm says Entrada’s lead programs focus on attractive disease niches.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on TRDA:
- Entrada Therapeutics to Participate in Guggenheim Genomic Medicines and Rare Disease Conference
- Entrada Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results
- Entrada Therapeutics expects cash to fund requirements into 2H25
- Entrada Therapeutics reports Q4 EPS (79c), consensus (83c)
- Entrada Therapeutics to Participate in Cowen 43rd Annual Health Care Conference
